Download Info Pack
Why Cordlife
About Cordlife


  • 2001

    Incorporated in Singapore as the first cord blood bank offering private cord blood banking services.

  • 2002

    Launched the first Cordlife facility at Camden Medical Centre in Singapore.

    Released the company’s first cord blood unit for a five-year-old boy suffering from leukaemia.

  • 2003

    Acquired Cytomatrix, a stem cell research company specialising in cell expansion technology.

  • 2004

    First and only cord blood bank in Southeast Asia to be listed on the Australian Securities Exchange (ASX).

    Became a founding member of the Asia Pacific Cord Blood Banks Consortium (APCBBC).

    Established marketing offices in Indonesia and Thailand.

  • 2005

    Received prestigious international accreditation from American Association of Blood Banks (AABB) for our facility in Singapore.

    First overseas Cordlife processing and storage facility launched in Hong Kong.

    Successfully acquired Biocell, the second largest private cord blood bank in Australia.

    Marketing office established in Philippines.

  • 2006

    Incorporated Cordlife Sciences India Pvt. Ltd., which was officially launched by Singapore Senior Minister and former Prime Minister Mr Goh Chok Tong in Kolkata.

    Sponsored the first cystic fibrosis cord blood collection in Australia.

    Acquired 20 percent of Netherlands tissue engineering company, PharmaCell BV.

  • 2007

    Globally recognised as “Technology Pioneer” by the World Economic Forum.

    Launched the first and only DEPKES licensed cord blood processing and storage facility in Indonesia through a joint venture partnership with the country’s largest pharmaceutical company, Kalbe Farma.

    Cordlife Hong Kong awarded ISO 9001:2000 certification.

    Biocell received Australia’s Therapeutic Goods Administration license (TGA).

  • 2008

    Received AABB reaccreditation for new Singapore flagship facility located in Singapore Science Park II

    Launched "Cordlife Cares" programme, the first corporate social responsibility of its kind in Singapore, which offers free private cord blood banking to families in need.

    Another Cordlife sales office opened in Medan, Indonesia’s third largest city.

    A second office in Hong Kong opened in Kowloon, strategically opposite Hong Kong Baptist Hospital which holds the record for the country’s highest number of private deliveries.

  • 2009

    India’s largest and most advanced facility opened, the first and only private cord blood bank in West Bengal. This fourth overseas facility is also the Group’s biggest thus far.

    BioCell merged with CellSense and was rebranded as “Australian Stem Cell Healthcare”, the largest private cord blood bank in Australia.

    Cordlife Hong Kong successfully certified by ISO for the second time.

    Cordlife India received ISO certification for its quality management system.

    Opened first and only cord blood processing and cryopreservation facility registered with the Department of Health in Manila at UP-AyalaLand Technohub.

    Global launch of Cordlife Quality Guarantee.

    Released cord blood unit for the first cerebral palsy treatment in Singapore.

    Appointed as Quality Advisor to Beijing Cord Blood Bank, one of the largest cord blood banks in China.

  • 2010

    Released cord blood unit for the first autologous treatment for neuroblastoma in Singapore.

    First in the Philippines to incorporate Sepax, a fully automated system for cord blood processing.

    Group CEO, Dr Steven Fang, honored as the Most Outstanding Entrepreneur by APEA.

    Released cord blood unit for the second cerebral palsy treatment in Singapore.

    First in India to introduce umbilical cord blood service for the cryopreservation of two cell lines.

    Secured strategic stake in China Stem Cells (South) Company Limited with US$10 million investment.

    Cordlife Indonesia received ISO 9001:2008 certification.

  • 2011

    Released cord blood unit for the first autologous treatment of neuroblastoma in Hong Kong.

    Released cord blood unit for the first sibling-related treatment of thalassaemia major in West Bengal.

    Demerger1 of Cordlife Singapore, Hong Kong and strategic interest in China from Cordlife Limited.

    1Cordlife Group Limited and Cordlife Limited are separate and independent companies. Both companies are affiliated through contractual agreements for the fulfillment of cross-border customer requests. The Cordlife brand and are properties of Cordlife Group Limited.
  • 2012

    Cordlife Philippines successfully achieved ISO 9001:2008 certification for the first time.

    More than 40,000 clients stored their precious stem cells with Cordlife.

  • 2013

    Cordlife Group Limited moved to its fully owned, 23,000sqft office and laboratory facility in A'Posh Bizhub, Yishun. The facility is capable of storing up to 650,000 cord blood units.

    First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*.

    Re-accredited by American Association of Blood Banks (AABB).

    Launched provision of umbilical cord lining banking services in Singapore with patented technology, CellOptima that is exclusively available at Cordlife capable of isolating EpSCs and MSCs, two types of stem cells present in the umbilical cord.

    Awarded 'Most Transparent Company Award' by SIAS Investors Choice

  • 2014

    More than 45,000 parents stored their child’s precious stem cells with Cordlife.

    Collaborated with Make-A-Wish Foundation® (Singapore) Ltd granting the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy.

  • 2015

    Cordlife Singapore received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices.

    Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy).

    Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund with a sponsorship of $150K to give young children from low-income families a chance in pre-school education.

    Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments.

    Received the 16th SIAS Investors Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category

    Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015.

    Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.

  • 2016

    First Singapore-based cord blood bank to launch in Myanmar and Vietnam.

    Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries.

    Launched Cordlife’s inaugural "Cordlife Donation Drive" in Singapore and raised donations-in-kind for Children’s Aid Society – Melrose Home.

  • 2017

    First cord blood bank in the Philippines to be AABB-accredited.

    More than 56,000 parents stored their child's precious stem cells with Cordlife.

    Launched NICE®, a clinically approved non-invasive prenatal test in Indonesia and Philippines.

    Launched Cordlife’s first-ever public "Cordlife Donation Drive" in Singapore and raised both cash and donations-in-kind for Singapore Children’s Society.

  • 2018

    Awarded "Best Family Cord Blood Bank Award" by Mummys Market.

    More than 60,000 parents stored their child’s precious stem cells with Cordlife.

*Conditions apply.

DCR No. : 1543, June 2019